Lifeward Ltd Expected to Post a Loss of $1.34 a Share - Earnings Preview

Lifeward Ltd Expected to Post a Loss of $1.34 a Share - Earnings Preview

Lifeward to Report Q2 2026 Financial Results

Lifeward Launches Pilot Program with Ottobock Care to Expand Access to ReWalk Personal Exoskeleton

Nano Dimension Names Moshe Rozenbaum Interim CEO

Lifeward Enters USD 5.58 Million Senior Secured Convertible Note Financing with Investors, Oramed Agent

Press Release: Lifeward Secures Growth Capital to Accelerate Commercial Expansion with up to $11.2 Million in Strategic Financing

Lifeward Q1 FY26 net loss widens to $10.79 million; revenue drops 22% to $3.92 million

Lifeward files initial beneficial ownership statement for Chief Medical Officer Rose Keith Dale

Lifeward names Keith D. Rose chief medical officer

Press Release: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Ltd reports results for the quarter ended March 31 - Earnings Summary

Lifeward delays Q1 10-Q filing, cites accounting work on strategic transaction

Lifeward Q1 Adj. EPS $(3.13) Misses $(1.25) Estimate, Sales $3.923M Miss $5.775M Estimate

Lifeward Q1 FY26 net loss more than doubles to $10.8 million; revenue falls 22% to $3.9 million

Press Release: Lifeward Reports First Quarter 2026 Financial Results

Lifeward files initial beneficial ownership statement for Oramed Pharmaceuticals stake

Lifeward Ltd expected to post a loss of $1.25 a share - Earnings Preview

Lifeward Ltd expected to post a loss of $1.25 a share - Earnings Preview